Michael G Natchus Selected Research

molnupiravir

2/2022	SARS-CoV-2 variant of concern type and biological sex affect efficacy of molnupiravir in dwarf hamster model of severe COVID-19.
10/2021	Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.
1/2021	SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.
1/2020	An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
1/2020	Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model.
10/2019	Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael G Natchus Research Topics

Disease

9	Infections 02/2022 - 01/2016
5	COVID-19 02/2022 - 01/2021
4	Human Influenza (Influenza) 10/2021 - 01/2018
4	Measles 01/2021 - 05/2012
3	Alphavirus Infections 10/2021 - 01/2018
3	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2019 - 05/2012
2	Body Weight (Weight, Body) 01/2020 - 01/2020
2	Neoplasms (Cancer) 05/2016 - 06/2011
2	Prostatic Neoplasms (Prostate Cancer) 05/2016 - 06/2011
1	Acute Lung Injury 02/2022
1	Virus Diseases (Viral Diseases) 12/2019
1	Brain Injuries (Brain Injury) 01/2019
1	Malaria 01/2012

Drug/Important Bio-Agent (IBA)

6	molnupiravirIBA 02/2022 - 10/2019
5	Pharmaceutical PreparationsIBA 10/2021 - 01/2016
5	Antiviral Agents (Antivirals)IBA 10/2021 - 01/2016
3	NucleosidesIBA 10/2020 - 05/2012
3	Progesterone FDA LinkGeneric 01/2019 - 05/2012
2	Biological ProductsIBA 02/2022 - 06/2011
2	VaccinesIBA 10/2021 - 01/2021
2	ERDRP-0519IBA 01/2021 - 01/2021
2	Viral RNAIBA 01/2021 - 05/2012
2	ProdrugsIBA 01/2020 - 10/2019
2	Ribavirin (Virazole)FDA LinkGeneric 12/2019 - 01/2018
2	2-amino-3,5-dihydroxyoctadecaneIBA 05/2016 - 06/2011
1	4'-fluorouridineIBA 05/2021
1	Interferon Type IIBA 01/2021
1	RNA-Dependent RNA Polymerase (RNA Dependent RNA Polymerase)IBA 01/2021
1	ChemokinesIBA 01/2021
1	CytokinesIBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	Fluorouracil (Carac)FDA LinkGeneric 12/2019
1	N(4)-hydroxycytidineIBA 11/2019
1	DNA-Directed RNA Polymerases (RNA Polymerase)IBA 05/2012
1	OximesIBA 05/2012
1	Antimalarials (Antimalarial Agents)IBA 01/2012
1	SphingolipidsIBA 01/2012
1	Docetaxel (Taxotere)FDA Link 06/2011
1	AndrogensIBA 06/2011

Therapy/Procedure

11	Therapeutics 01/2022 - 06/2011
1	Injections 05/2012